GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Ernexa Therapeutics ERNA · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.05

+9.04%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Ernexa Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Ernexa Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ERNA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $582,000.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
29 Aug 1991
Employees
9
Head office
1035 CAMBRIDGE STREET, CAMBRIDGE, MA, 02141
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. James BristolIndependent Chairman of the Board$167,200
  • Mr. Sanjeev LutherPresident, Chief Executive Officer, Director, since 2024$3.0m
  • Ms. Sandra GurrolaSenior Vice President - Finance$385,198
  • Mr. Peter CicalaIndependent Director$119,424
  • Dr. Elena RatnerIndependent Director
  • Mr. William WexlerIndependent Director$112,288

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
65
Environment
67
Social
86
Governance
41
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Eterna Therapeutics has over 100 patents in mRNA cell engineering technology.
  • The company's mRNA gene-editing technology corrects disease-causing DNA mutations.
  • Eterna Therapeutics focuses on advanced therapies using mRNA cell engineering.

Weaknesses

  • Eterna Therapeutics employs only 9 full-time employees.
  • The company is headquartered in Cambridge, Massachusetts, a high-cost location.
  • Eterna Therapeutics has no listed revenue or financial data available.

Opportunities

  • Eterna Therapeutics' mRNA technology platform can be applied to cancer treatments.
  • The firm's NoveSlice and UltraSlice gene-editing proteins offer new therapeutic applications.
  • Eterna Therapeutics can expand its mRNA delivery system, ToRNAdo, for broader use.

Threats

  • Eterna Therapeutics faces competition from other biotechnology firms in the US.
  • The company's small size may limit its ability to secure large-scale funding.
  • Regulatory challenges in the Health Care sector could impact mRNA therapies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.